DK2139479T3 - 4-[2-(4-methylphenylsulfanyl)phenyl]piperidin med kombineret serotonin og norepineprhin genoptagelsesinhibering til behandlingen af adhd, melankoli, behandling af resistent depression eller restsymptomer af depression - Google Patents

4-[2-(4-methylphenylsulfanyl)phenyl]piperidin med kombineret serotonin og norepineprhin genoptagelsesinhibering til behandlingen af adhd, melankoli, behandling af resistent depression eller restsymptomer af depression

Info

Publication number
DK2139479T3
DK2139479T3 DK08715618.8T DK08715618T DK2139479T3 DK 2139479 T3 DK2139479 T3 DK 2139479T3 DK 08715618 T DK08715618 T DK 08715618T DK 2139479 T3 DK2139479 T3 DK 2139479T3
Authority
DK
Denmark
Prior art keywords
treatment
norepineprhin
methylphenylsulphanyl
melanic
adhd
Prior art date
Application number
DK08715618.8T
Other languages
English (en)
Inventor
Tine Bryan Stensboel
Silke Miller
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of DK2139479T3 publication Critical patent/DK2139479T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK08715618.8T 2007-03-20 2008-03-14 4-[2-(4-methylphenylsulfanyl)phenyl]piperidin med kombineret serotonin og norepineprhin genoptagelsesinhibering til behandlingen af adhd, melankoli, behandling af resistent depression eller restsymptomer af depression DK2139479T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200700423 2007-03-20
PCT/DK2007/050076 WO2007144006A1 (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
PCT/DK2008/050064 WO2008113360A2 (en) 2007-03-20 2008-03-14 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression

Publications (1)

Publication Number Publication Date
DK2139479T3 true DK2139479T3 (da) 2013-02-11

Family

ID=39575680

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08715618.8T DK2139479T3 (da) 2007-03-20 2008-03-14 4-[2-(4-methylphenylsulfanyl)phenyl]piperidin med kombineret serotonin og norepineprhin genoptagelsesinhibering til behandlingen af adhd, melankoli, behandling af resistent depression eller restsymptomer af depression
DK08758225.0T DK2167085T3 (da) 2007-03-20 2008-06-13 4- [2- (4-methylphenylsulfanyl) phenyl]piperidin til behandling af irritabel tarmsyndrom (ibs)

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08758225.0T DK2167085T3 (da) 2007-03-20 2008-06-13 4- [2- (4-methylphenylsulfanyl) phenyl]piperidin til behandling af irritabel tarmsyndrom (ibs)

Country Status (27)

Country Link
US (2) US20100144788A1 (da)
EP (2) EP2139479B1 (da)
JP (1) JP5388867B2 (da)
KR (1) KR20090125775A (da)
CN (2) CN101674830B (da)
AR (1) AR065798A1 (da)
AU (1) AU2008228639B2 (da)
BR (1) BRPI0808831A2 (da)
CA (1) CA2684556C (da)
CL (1) CL2008000796A1 (da)
CO (1) CO6220957A2 (da)
CY (2) CY1113965T1 (da)
DK (2) DK2139479T3 (da)
EA (1) EA017407B1 (da)
ES (2) ES2399305T3 (da)
HR (1) HRP20130049T1 (da)
IL (1) IL200954A (da)
MX (1) MX2009009934A (da)
MY (1) MY163537A (da)
NZ (1) NZ579723A (da)
PL (2) PL2139479T3 (da)
PT (2) PT2139479E (da)
RS (2) RS52676B (da)
SI (1) SI2139479T1 (da)
TW (1) TWI432194B (da)
UA (2) UA97660C2 (da)
WO (1) WO2008113360A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20110412T1 (hr) * 2006-06-16 2011-06-30 H. Lundbeck A/S Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombiniranom inhibicijom reapsorpcije serotonina i norepinefrina za liječenje neuropatskih bolova
WO2008151632A1 (en) * 2007-06-15 2008-12-18 H.Lundbeck A/S 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs)
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
EP2564837B1 (en) * 2010-04-30 2019-01-30 Takeda Pharmaceutical Company Limited Enteric tablet
US8745134B1 (en) 2011-03-04 2014-06-03 Zynga Inc. Cross social network data aggregation
US8332488B1 (en) 2011-03-04 2012-12-11 Zynga Inc. Multi-level cache with synch
US8347322B1 (en) 2011-03-31 2013-01-01 Zynga Inc. Social network application programming interface
US10135776B1 (en) 2011-03-31 2018-11-20 Zynga Inc. Cross platform social networking messaging system
US8522137B1 (en) 2011-06-30 2013-08-27 Zynga Inc. Systems, methods, and machine readable media for social network application development using a custom markup language
WO2018002115A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004539B1 (ru) * 1998-05-22 2004-06-24 Эли Лилли Энд Компани Комбинационная терапия для лечения резистентной депрессии
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
SI1626720T1 (sl) * 2003-04-04 2008-12-31 Lundbeck & Co As H Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina
JP2006522027A (ja) * 2003-04-04 2006-09-28 ハー・ルンドベック・アクチエゼルスカベット セロトニン再取り込み阻害剤としての４−（２−フェニルオキシフェニル）−ピペリジンまたは−１，２，３，６−テトラヒドロピリジン誘導体
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
DE102006028034A1 (de) * 2006-06-14 2007-12-20 Leifheit Ag Bürste und Kehrgerät mit Bürste
HRP20110412T1 (hr) * 2006-06-16 2011-06-30 H. Lundbeck A/S Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombiniranom inhibicijom reapsorpcije serotonina i norepinefrina za liječenje neuropatskih bolova
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter

Also Published As

Publication number Publication date
CN101674830B (zh) 2012-05-09
CO6220957A2 (es) 2010-11-19
CN101674830A (zh) 2010-03-17
AU2008228639B2 (en) 2012-12-13
CN101646438B (zh) 2012-04-11
HK1142007A1 (en) 2010-11-26
PL2139479T3 (pl) 2013-05-31
MY163537A (en) 2017-09-15
EA200970871A1 (ru) 2010-04-30
HRP20130049T1 (hr) 2013-02-28
PT2139479E (pt) 2013-02-20
UA99611C2 (ru) 2012-09-10
RS53138B (sr) 2014-06-30
CY1114774T1 (el) 2016-12-14
SI2139479T1 (sl) 2013-04-30
WO2008113360A3 (en) 2008-11-13
EP2167085A1 (en) 2010-03-31
IL200954A0 (en) 2010-05-17
CY1113965T1 (el) 2016-07-27
CA2684556C (en) 2013-01-08
BRPI0808831A2 (pt) 2014-08-26
TW200848032A (en) 2008-12-16
EP2139479A2 (en) 2010-01-06
AU2008228639A1 (en) 2008-09-25
CA2684556A1 (en) 2008-09-25
US20100137366A1 (en) 2010-06-03
EA017407B1 (ru) 2012-12-28
TWI432194B (zh) 2014-04-01
UA97660C2 (ru) 2012-03-12
WO2008113360A2 (en) 2008-09-25
MX2009009934A (es) 2009-09-24
PL2167085T3 (pl) 2014-08-29
DK2167085T3 (da) 2014-02-03
CL2008000796A1 (es) 2008-09-26
NZ579723A (en) 2011-07-29
AR065798A1 (es) 2009-07-01
CN101646438A (zh) 2010-02-10
KR20090125775A (ko) 2009-12-07
PT2167085E (pt) 2014-02-17
US20100144788A1 (en) 2010-06-10
RS52676B (sr) 2013-06-28
EP2139479B1 (en) 2012-12-12
JP5388867B2 (ja) 2014-01-15
JP2010521502A (ja) 2010-06-24
IL200954A (en) 2014-12-31
ES2445400T3 (es) 2014-03-03
US8507526B2 (en) 2013-08-13
EP2167085B1 (en) 2013-12-25
ES2399305T3 (es) 2013-03-27

Similar Documents

Publication Publication Date Title
DK2139479T3 (da) 4-[2-(4-methylphenylsulfanyl)phenyl]piperidin med kombineret serotonin og norepineprhin genoptagelsesinhibering til behandlingen af adhd, melankoli, behandling af resistent depression eller restsymptomer af depression
NL301090I1 (nl) Entrectinib, dan wel tautomeren, of farmaceutisch aanvaardbare zouten daarvan
DK2426106T3 (da) Piperidin- og piperazinderivat til behandling af tumorer
DK1999225T3 (da) Fremgangsmåder til behandling af borehuller med genanvendelige fluider
RU2465270C3 (ru) Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она
DK2069374T4 (da) Krystallinske solvater af (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl)phenyl)-d-glucitolderivater med alkoholer som sglt2-inhibitorer til behandling af diabetes
DK1812528T3 (da) Viskoelastiske tensidfluider med forbedret retablering af formforandring, forbedret reologi og stabilitet
DK1737461T3 (da) Carbolin-derivater til inhibering af angiogenese
NO345119B1 (no) Fremgangsmåte for å forhindre og/eller hemme dannelse av uorganiske fluoridavsetninger
DK2142193T3 (da) 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine som forbindelse med kombineret serotoninoptagelse, 5-HT3 og 5-HT1A aktivitet til behandling af smerte eller restsymptomer i depression i forbindelse med søvn og kognition
DK3231798T3 (da) Thiazol-E-mellemprodukter, der er nyttige ved fremstillingen af RAF-kinasehæmmer
DK2398785T3 (da) Oprensning af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazin
NO20082223L (no) Fremgangsmåte for inhibering av FLT3-kinase
DK1922307T3 (da) Heterocykliske inhibitorer af MEK og fremgangsmåder til anvendelse heraf
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
DK2046331T3 (da) Anvendelse af 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dion til behandling af mantle cellelymfom
DE602005023266D1 (de) Azabenzofuransubstituierte thioharnstoffe als inhibitoren der virusreplikation
EP1771442A4 (en) INHIBITORS OF VIRAL POLYMERASE
DK2358691T3 (da) Fremgangsmåde til fremstilling af piperazinforbindelser og hydrochloridsalte deraf
DK2158199T3 (da) Piperidinforbindelser og anvendelser deraf
PL3689346T3 (pl) 3,6-Dipodstawione sole ksantyliowe do leczenia tauopatii
DK2358675T3 (da) 4-[2-(2-Fluorphenoxymethyl)phenyl]piperidinforbindelser
DK1843794T3 (da) Fremgangsmåde til bekæmpelse af mikrobiologisk kontaminering, opnåede mineralsuspensioner og deres anvendelse
DK2162238T3 (da) Overfladebehandling af termisk modificeret træ
DK2763981T3 (da) Fremgangsmåde til fremstilling af 1-(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-on-hydrochlorid og mellemprodukter anvendt deri